Conditions: Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreas Metastases; Adenocarcinoma
Interventions: Drug: Paricalcitol (Zemplar)
Sponsors: HonorHealth Research Institute; Barts Cancer Institute; Abramson Cancer Center at Penn Medicine; Salk Institute for Biological Studies; Mayo Clinic; Princeton University; Imaging Endpoints; Translational Genomics Research Institute; Stand Up To Cancer; Cancer Research UK; Lustgarten Foundation; University of California, San Diego
Completed
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
